Mobitz type II atrioventricular block

Summary

Mobitz type II atrioventricular block (MONDO:0001261) is a disease and 1 clinical trial. A subtype of second-degree atrioventricular block — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Mobitz type II atrioventricular block
Mondo ID	MONDO:0001261
DOID	DOID:11312
NCIT	C62018
SNOMED CT	28189009
UMLS	C0155700
MedGen	102340
GARD	0022910
Is cancer (heuristic)	no

Also known as: AV block second degree Mobitz type II · AV block second degree Möbitz type II · Mobitz (type) II atrioventricular block · Mobitz II · Mobitz type II second degree AV block · Möbitz II · Möbitz type II second degree AV block · second degree atrioventricular block Mobitz type II · second degree atrioventricular block Möbitz type II · type 2 2nd degree AV block · type 2 second degree AV block · type II second degree atrioventricular block · type II second degree AV block

Disease family

This is a subtype of second-degree atrioventricular block. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › heart conduction disease › atrioventricular block › second-degree atrioventricular block › Mobitz type II atrioventricular block

Related subtypes (1): Mobitz type I atrioventricular block

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06474819	Not specified	RECRUITING	Left Septal or Deep Septal Pacing to Prevent Pacing-induced Cardiomyopathy